Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
First two patients dosed in the EXACT studyTopline data from the initial 16-week placebo-controlled portion of the study expected mid-2027;...
Read moreDetails